Goldman Sachs Group Inc. Sells 134,637 Shares of Dianthus Therapeutics, Inc. $DNTH

Key Points

• Goldman Sachs Group Inc. reduced its stake in Dianthus Therapeutics, Inc. by 64.7%, owning 73,430 shares worth approximately $1.33 million after selling 134,637 shares in the first quarter.
• Other institutional investors, such as Octagon Capital Advisors and Vestal Point Capital, increased their holdings in Dianthus, with Vestal Point raising its stake by 58.1% to over 1.7 million shares.
• Dianthus reported a loss of ($0.88) earnings per share for the last quarter, missing analysts' expectations, and its current average rating among analysts is "Buy" with a target price of $61.57.

Goldman Sachs Group Inc. trimmed its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 64.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,430 shares of the company's stock after selling 134,637 shares during the quarter. Goldman Sachs Group Inc. owned 0.23% of Dianthus Therapeutics worth $1,332,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in DNTH. Octagon Capital Advisors LP boosted its stake in shares of Dianthus Therapeutics by 11.0% in the 1st quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company's stock valued at $42,478,000 after purchasing an additional 231,500 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock valued at $280,000 after purchasing an additional 618 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in Dianthus Therapeutics by 5.0% during the first quarter. Adage Capital Partners GP L.L.C. now owns 189,000 shares of the company's stock worth $3,428,000 after buying an additional 9,000 shares during the last quarter. ADAR1 Capital Management LLC increased its holdings in Dianthus Therapeutics by 3.4% during the first quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company's stock worth $332,000 after buying an additional 602 shares during the last quarter. Finally, Vestal Point Capital LP increased its holdings in Dianthus Therapeutics by 58.1% during the first quarter. Vestal Point Capital LP now owns 1,700,069 shares of the company's stock worth $30,839,000 after buying an additional 625,069 shares during the last quarter. 47.53% of the stock is owned by institutional investors.

Insider Activity at Dianthus Therapeutics

In other news, CFO Ryan Savitz sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 16.56% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on DNTH. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Monday, September 8th. Stifel Nicolaus lifted their target price on shares of Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a "buy" rating in a research note on Friday, September 12th. Wedbush lifted their target price on shares of Dianthus Therapeutics from $42.00 to $44.00 and gave the stock an "outperform" rating in a research note on Friday, September 12th. Robert W. Baird lifted their target price on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 9th. Finally, William Blair initiated coverage on shares of Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an "outperform" rating for the company. Nine analysts have rated the stock with a Buy rating, According to data from MarketBeat, Dianthus Therapeutics currently has a consensus rating of "Buy" and an average price target of $61.57.

Dianthus Therapeutics Trading Up 1.5%

Shares of DNTH stock traded up $0.56 during trading hours on Tuesday, reaching $38.32. The stock had a trading volume of 166,545 shares, compared to its average volume of 406,048. The stock's fifty day simple moving average is $25.18 and its 200 day simple moving average is $21.20. Dianthus Therapeutics, Inc. has a 12 month low of $13.36 and a 12 month high of $39.87. The firm has a market capitalization of $1.23 billion, a PE ratio of -11.79 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. As a group, equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.